Allstate Analysts Split as Insiders Head for the Exits

Allstate heads into its October 28 earnings date with a notable divergence: the Street is actively debating the stock's valuation ceiling while corporate insiders have been selling in size.

The insider picture is the most concrete signal this week. Over the past 90 days, net insider selling has reached roughly $23.8 million in open-market transactions — a material outflow for a stock trading near $257. The bulk came from two executives in early August: John Dugenske sold nearly $9 million across three tranches on August 7, and Mario Rizzo followed with over $14.8 million in sales on August 11 — the same day Rizzo exercised options at $92.46. Neither sale was flagged as being under a pre-arranged 10b5-1 plan, which makes the timing more notable than a routine programmatic exit. The most recent activity was a small tax-withholding transaction in early September, effectively housekeeping rather than conviction. Still, the directional read from the 90-day window is unambiguous: the people closest to the business have been net sellers into the stock's recent strength.

The analyst picture is more fractured, and the disagreement has sharpened over the past month. The post-earnings wave in early August was broadly constructive — JPMorgan raised its target to $292, Goldman lifted to $280, and Mizuho went to $300 — all maintaining positive or neutral ratings after Allstate's results showed auto policies-in-force growing and reserve developments coming in favourable. But the tone has since shifted. KBW's Meyer Shields cut to Underperform on August 20, lowering his target to $250, citing combined-ratio concerns and competitive pricing pressure in personal lines. Argus Research followed with a downgrade to Hold on August 28 — no target attached. Then, just today, Mizuho's Yaron Kinar trimmed his Outperform target modestly from $300 to $297, maintaining the bullish rating but signalling some recalibration. The mean consensus price target is around $275, implying roughly 7% upside from current levels — but Citi has a Sell with a $240 target, and KBW's $250 floor is now below the current price. The consensus is positive on balance, but the distribution of views has widened.

Short interest and the borrow market tell a very different story from the insider and analyst noise. Bears have not built a meaningful position. Short interest is just 2.2% of the free float — low by any measure — and while it has edged up about 6.5% over the past week, the absolute level remains negligible. The lending market is extraordinarily loose: availability is at 3,643%, meaning there are roughly 36 shares available to borrow for every one currently shorted. Borrowing costs hover near 0.41% annually, near the cheapest level of the recent range. The ORTEX short score of 34 reflects this lack of bearish conviction. Options positioning is also structurally defensive for this stock — the put/call ratio is 1.49, right in line with its 20-day average of 1.50, and the z-score of -0.22 shows no unusual tilt in either direction. The borrow market and derivatives desk are not pricing any near-term stress.

On valuation, Allstate trades at 8.7x trailing earnings and 1.7x book — reasonable for the sector, though the PE has drifted up about 7% over the past 30 days as the stock lagged slightly. The EV/EBIT factor ranks in the 89th percentile, suggesting the market still sees relative value here. The stock is up 1.5% on the week but has given back 1.6% over the past month. Among close peers, PGR gained nearly 3% on the week and THG added 3.7%, meaning Allstate has underperformed the group modestly in the short run despite its stronger year-to-date track record.

The October 28 earnings print is the next real test. The recent history shows mixed reactions: Allstate gained nearly 5% the day after its August 2026 results, but the five-day window saw a -2.6% reversal. The July 2026 print went the other way — down 2.6% on the day, down 2.9% over five days. What to watch into that date: whether the combined-ratio trajectory gives KBW's bearish case fresh ammunition, and whether the insider selling pace of the past six weeks reflects concern about the competitive pricing environment that bears have flagged, or simply routine post-earnings monetisation.